NEIMETH INTERNATIONAL PHARMACEUTICALS PLC |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.85 NGN | 0.00% |
|
-6.57% | -4.64% |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Take advantage of the offer
* See conditions on site
| Sales 2022 | 2.92B 2.08M | Sales 2023 | 2.21B 1.57M | Capitalization | 8.29B 5.9M |
|---|---|---|---|---|---|
| Net income 2022 | -325M -231K | Net income 2023 | -2.58B -1.84M | EV / Sales 2022 | 2.03 x |
| Net Debt 2022 | 3.2B 2.28M | Net Debt 2023 | 2.05B 1.46M | EV / Sales 2023 | 4.68 x |
| P/E ratio 2022 |
-8.36
x | P/E ratio 2023 |
-3.21
x | Employees | 202 |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 28.29% |
More Fundamentals
* Assessed data
More news
More press releases
| 1 week | -6.57% | ||
| Current month | -6.57% | ||
| 1 month | +1.65% | ||
| 3 months | -14.35% | ||
| 6 months | +17.83% | ||
| Current year | -4.64% |
1 week
1.70
1.85
1 month
1.641.98
Current year
1.642.20
1 year
1.392.45
3 years
1.262.45
5 years
0.372.91
10 years
0.352.91
| Managers | Title | Age | Since |
|---|---|---|---|
Valentine Okelu
CEO | Chief Executive Officer | - | 23-08-15 |
| Director of Finance/CFO | - | - | |
| Chief Administrative Officer | - | 91-12-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | - | 97-01-31 | |
| Chairman | 62 | 04-01-31 | |
Valentine Okelu
CEO | Chief Executive Officer | - | 23-08-15 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-07 | 1.85 | 0.00% | 23 058 |
| 24-05-07 | 1.85 | 0.00% | 76,123 |
| 24-05-06 | 1.85 | +8.82% | 587,361 |
| 24-05-03 | 1.7 | -5.56% | 347,759 |
| 24-05-02 | 1.8 | -9.09% | 307,500 |
End-of-day quote Nigerian S.E., May 07, 2024
More quotes
Neimeth International Pharmaceuticals Plc is engaged in the manufacturing and marketing of pharmaceuticals and animal health products. The Company operates through two segments: Pharmaceuticals product group and Animal health product group. Pharmaceuticals product group is engaged in the marketing and sales of the Company's branded products and the products under the consumer product group. Animal health product group is engaged in the marketing and sales of poultry and animal range of anthelmintics, as well as production medicaments. Its products include Ethical Products, Veterinary Products, and Healthcare Products. Its Ethical Products include Ciklavit, Flucosyd, Amlovar, Co-Amoxiclav, Gyno-Tiocosid, Miniplus, Neimelyn, Norduet, and Normoretic. Veterinary Products include Neimeth Piperazine, Neimycin Soluble Powder, and Neiva Stress. Its Healthcare Products include Antimal, Homtamin G, Urah, Nimartem, and Pancemol. The Company operates in two geographic regions: Nigeria and Ghana.
Sector
Pharmaceuticals
Sell
Buy
Mean consensus
SELL
Number of Analysts
1
Last Close Price
1.85
NGN
Average target price
1.75
NGN
Spread / Average Target
-5.41%
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -4.64% | 5.71M | |
| +32.95% | 700B | |
| -4.97% | 358B | |
| +18.83% | 330B | |
| +3.54% | 287B | |
| +15.70% | 236B | |
| +6.68% | 202B | |
| -9.08% | 197B | |
| +6.70% | 161B | |
| -1.81% | 157B |
- Stock Market
- Equities
- NEIMETH Stock